Back to Results
First PageMeta Content
Calcium channel blockers / Dihydropyridines / Nitrobenzenes / Ethers / Nimodipine / Pharmaceutical drug / Route of administration / Package insert / Chemistry / Organic chemistry / Pharmacology


IMPORTANT DRUG WARNING February 2006 Dear Healthcare Professional: Bayer Pharmaceuticals Corporation (Bayer) would like to inform you that inadvertent intravenous (IV) administration of the contents of Nimotop® (nimodip
Add to Reading List

Open Document

File Size: 153,44 KB

Share Result on Facebook

City

Montvale / /

Company

BAYER HEALTHCARE RX BAYER PHARMACEUTICALS CORPORATION / Bayer Pharmaceuticals Corporation / Drug Safety Assurance Bayer Pharmaceuticals Corporation / Hess / /

Country

United States / /

IndustryTerm

healthcare professionals / /

MedicalCondition

subarachnoid hemorrhage / bradycardia / cardiac arrest / clinically significant hypotension / ruptured intracranial berry aneurysms / INCLUDING CARDIAC ARREST / HYPOTENSION / /

MedicalTreatment

surgery / /

Organization

DOSAGE AND ADMINISTRATION / U.S. PI / WARNINGS / WARNINGS DEATH DUE TO INADVERTENT INTRAVENOUS ADMINISTRATION / NG/PEG administration / /

Person

Ed Tucker / /

/

Position

Director / Clinical Content Physicians / PRECAUTIONS General / Vice President / /

Product

Nimotop / nimodipine / /

ProvinceOrState

New Jersey / /

PublishedMedium

the Product Identification Guide / /

SocialTag